智通财经APP获悉，周一，疫苗巨头Moderna(MRNA.US)、基因疗法公司Sarepta Therapeutics(SRPT.US)跌近9%，分别报28.34美元及64.09美元。消息面上，美国食品和药物管理局(FDA)官员Dr. Peter Marks宣布辞职，他领导着FDA生物制品评估和研究中心(CBER)，是FDA内部最知名的职业官员之一。作为生物技术行业的重要监管者，Marks对基因疗法和疫苗的审批具有关键影响力，他长期以来支持加快罕见病药物的审批进程，帮助许多生物科技公司推动创新疗法上市。此外，Marks在新冠疫苗研发方面也发挥了重要作用。
由于Marks的离任可能影响FDA未来对创新药物的监管态度，生物科技投资者情绪急剧恶化，导致相关股票大幅下跌。市场普遍担忧，FDA在生物制品审批方面的政策可能会趋于保守，从而影响未来基因疗法和疫苗的推进速度。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
No relevant data is available